Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 3/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23993715 | 1.00 | NT5E (0.38) | NT5EGRIA1JAK2TYK2DAO | |
| SCHEMBL23993916 | 0.90 | NT5E (0.39) | NT5EGRIA1JAK2TYK2 | |
| SCHEMBL30224587 | 0.90 | NT5E (0.39) | NT5EGRIA1JAK2TYK2 | |
| SCHEMBL23993732 | 0.90 | NT5E (0.39) | NT5EGRIA1JAK2TYK2 | |
| SCHEMBL25005476 | 0.87 | NT5E (0.41) | NT5EGRIA1JAK2TYK2 | |
| SCHEMBL23995102 | 0.87 | NT5E (0.41) | NT5EGRIA1JAK2TYK2 | |
| SCHEMBL25005409 | 0.87 | NT5E (0.41) | NT5EGRIA1JAK2TYK2 | |
| SCHEMBL23993775 | 0.87 | NT5E (0.41) | NT5EGRIA1JAK2TYK2 | |
| SCHEMBL25004541 | 0.83 | NT5E (0.40) | NT5EJAK2TYK2 | |
| SCHEMBL30224735 | 0.83 | NT5E (0.40) | NT5EJAK2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12110294-B2 | CD73 compounds | GILEAD SCIENCES, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| EP-4143194-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20230039553-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| WO-2021222522-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | NT5E 3/4885GRIA1 3025/4885JAK2 1484/4885 |
| US-12110294-B2 | CD73 compounds | ENTPD5, ENTPD1, NT5E | NT5E 3/4885GRIA1 2851/4885JAK2 1668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.